Phosphoproteins and the dawn of functional phenotyping

Pathobiology

Volumn 78, Issue 2, 2011, Pages 115-121

  Bodo, J ^a   Hsi, E D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hematopathology; Immunofluorescence; Immunohistochemistry; Phosphoprotein; Quantification; Quantum dots

Indexed keywords

DASATINIB; PHOSPHOPROTEIN;

ANTIBODY SPECIFICITY; CANCER INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

ANTIBODY SPECIFICITY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHENOTYPE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTEOMICS; QUALITY CONTROL; QUANTUM DOTS; SIGNAL TRANSDUCTION; SPECIMEN HANDLING;

EID: 79959298407     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000296015     Document Type: Review

References (30)

1. Burnett G, Kennedy EP: The enzymatic phosphorylation of proteins. J Biol Chem 1954; 211: 969-980.
2. Mandell JW: Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 2003; 163: 1687-1698.
3. Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ: The Janus kinases (Jaks). Genome Biol 2004; 5: 253.
4. Reiter A, Walz C, Watmore A, et al: The t(8; 9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65: 2662-2667. (Pubitemid 40490065)
5. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
6. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397. (Pubitemid 40544655)
7. Aboudola S, Murugesan G, Szpurka H, et al: Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol 2007; 31: 233-239. (Pubitemid 46175024)
8. Gibson SE, Schade AE, Szpurka H, Bak B, Maciejewski JP, Hsi ED: Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F. Hum Pathol 2008; 39: 1111-1114.
9. Zhang S, Fukuda S, Lee Y, et al: Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 2000; 192: 719-728.
10. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT: Genomic structure of human FLT3: implications for mutational analysis. Br J Haematol 2001; 113: 1076-1077. (Pubitemid 32634779)
11. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335. (Pubitemid 34627197)
12. Yokota S, Kiyoi H, Nakao M, et al: Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia 1997; 11: 1605-1609. (Pubitemid 27458595)
13. Gilliland DG, Griffin JD: Role of FLT3 in leukemia. Curr Opin Hematol 2002; 9: 274-281. (Pubitemid 34596870)
14. Bunting KD, Xie XY, Warshawsky I, Hsi ED: Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD. Blood 2007; 110: 2775-2776. (Pubitemid 47523213)
15. Bodo J, Durkin L, Hsi ED: Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology. J Histochem Cytochem 2009; 57: 701-708.
16. Zuluaga TT, Hsieh FH, Bodo J, Dong HY, Hsi ED: Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation. Br J Haematol 2007; 139: 31-40. (Pubitemid 47389913)
17. Luo FR, Barrett YC, Yang Z, et al: Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008; 62: 1065-1074.
18. Chen Z, Lee FY, Bhalla KN, Wu J: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006; 69: 1527-1533.
19. Schittenhelm MM, Shiraga S, Schroeder A, et al: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473-481. (Pubitemid 43166056)
20. Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541. (Pubitemid 43882349)
21. Tokarski JS, Newitt JA, Chang CY, et al: The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66: 5790-5797. (Pubitemid 43927133)
22. Burns JA, Li Y, Cheney CA, et al: Choice of fixative is crucial to successful immunohistochemical detection of phosphoproteins in paraffin-embedded tumor tissues. J Histochem Cytochem 2009; 57: 257-264.
23. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G: Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005; 11: 4338-4340.
24. Espina V, Edmiston KH, Heiby M, et al: A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008; 7: 1998-2018.
25. Patstone G, Maher PA: Phosphotyrosine-containing proteins are concentrated in differentiating cells during chicken embryonic development. Growth Factors 1993; 9: 243-252. (Pubitemid 23310712)
26. Fantin VR, Loboda A, Paweletz CP, et al: Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008; 68: 3785-3794.
27. Rikova K, Guo A, Zeng Q, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203. (Pubitemid 350235027)
28. Krutzik PO, Irish JM, Nolan GP, Perez OD: Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004; 110: 206-221. (Pubitemid 38402001)
29. Zheng H, Hu P, Quinn DF, Wang YK: Phosphotyrosine proteomic study of interferon alpha signaling pathway using a combination of immunoprecipitation and immobilized metal affinity chromatography. Mol Cell Proteomics 2005; 4: 721-730. (Pubitemid 40879601)
30. Hsi ED: A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory. Arch Pathol Lab Med 2001; 125: 289-294.